Significant progress has been made in neurodegenerative disease research through proteomics, genetics, and novel therapies. The Global Neurodegeneration Proteomics Consortium released one of the largest protein datasets, revealing biomarkers specific to Alzheimer's, Parkinson’s, frontotemporal dementia, and ALS. Researchers at Stanford developed ultra-sensitive voltage sensors to map brain activity with cell-type specificity. Collaborative efforts like the ASAP initiative expanded datasets characterizing Parkinson’s disease brain cells. Additionally, companies like Biosplice and JCR are advancing therapies targeting Alzheimer’s and neurodegeneration pathways, highlighting multi-dimensional approaches to diagnosis and treatment development.